Genmab A (GMAB) Non Operating Income (2018 - 2026)

Genmab A has reported Non Operating Income for 6 years, with the latest figure at -$106.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 289.29% year-over-year to -$106.0 million; the trailing twelve-month figure through Mar 2026 stood at -$84.0 million (down 163.64% YoY), and the FY2025 full-year result was $139.0 million, down 60.73% from the prior year.
• Non Operating Income for Q1 2026 stood at -$106.0 million, down from $23.0 million in the prior quarter.
• The five-year high for Non Operating Income was $133.0 million in Q1 2024, with the low at -$106.0 million in Q1 2026.
• Historically, Non Operating Income has averaged $9.8 million across 3 years, with a median of $23.0 million in 2025.
• Annual changes were most pronounced in 2025 — Non Operating Income surged 140.35% — and 2026, when it slumped 289.29%.
• Genmab A's Non Operating Income stood at -$57.0 million in 2024, then surged by 140.35% to $23.0 million in 2025, then tumbled by 560.87% to -$106.0 million in 2026.
• The last three Non Operating Income figures came in at -$106.0 million (Q1 2026), $23.0 million (Q3 2025), and $56.0 million (Q1 2025), per Business Quant data.